Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 21


Statins and Aspirin use in HIV-infected people: gap between European AIDS Clinical Society guidelines and clinical practice: the results from HIV-HY study.

De Socio GV, Ricci E, Parruti G, Calza L, Maggi P, Celesia BM, Orofino G, Madeddu G, Martinelli C, Menzaghi B, Taramasso L, Penco G, Carenzi L, Franzetti M, Bonfanti P.

Infection. 2016 Oct;44(5):589-97. doi: 10.1007/s15010-016-0893-z.


Factors involved in continuance of atazanavir-based regimens: Results from a cohort of HIV1-positive patients.

Giacomelli A, Oreni L, Franzetti M, Di Cristo V, Colella E, Ridolfo AL, Galli M, Rusconi S.

Antiviral Res. 2016 May;129:52-7. doi: 10.1016/j.antiviral.2016.02.010.


HIV-1 A1 Subtype Epidemic in Italy Originated from Africa and Eastern Europe and Shows a High Frequency of Transmission Chains Involving Intravenous Drug Users.

Lai A, Bozzi G, Franzetti M, Binda F, Simonetti FR, De Luca A, Micheli V, Meraviglia P, Bagnarelli P, Di Biagio A, Monno L, Saladini F, Zazzi M, Zehender G, Ciccozzi M, Balotta C.

PLoS One. 2016 Jan 11;11(1):e0146097. doi: 10.1371/journal.pone.0146097.


Muscle symptoms and creatine phosphokinase elevations in patients receiving raltegravir in clinical practice: Results from the SCOLTA project long-term surveillance.

Madeddu G, De Socio GV, Ricci E, Quirino T, Orofino G, Carenzi L, Franzetti M, Parruti G, Martinelli C, Vichi F, Penco G, Dentone C, Celesia BM, Maggi P, Libertone R, Bagella P, Di Biagio A, Bonfanti P; C.I.S.A.I. Group, Italy..

Int J Antimicrob Agents. 2015 Mar;45(3):289-94. doi: 10.1016/j.ijantimicag.2014.10.013.


Factors involved in treatment durability and immunological recovery in a cohort of HIV-positive patients receiving atazanavir-based regimens.

Giacomelli A, Oreni L, Franzetti M, Di Cristo V, Vergani B, Morosi M, Colella E, Galli M, Rusconi S.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19830. doi: 10.7448/IAS.17.4.19830.


Changes in the incidence of severe thrombocytopenia and its predisposing conditions in HIV-infected patients since the introduction of highly active antiretroviral therapy.

Franzetti M, Adorni F, Oreni L, Van Den Bogaart L, Resnati C, Milazzo L, Antinori S, Galli M, Ridolfo AL.

J Acquir Immune Defic Syndr. 2014 Dec 15;67(5):493-8. doi: 10.1097/QAI.0000000000000347.


Trends and correlates of HIV-1 resistance among subjects failing an antiretroviral treatment over the 2003-2012 decade in Italy.

Franzetti M, Violin M, Antinori A, De Luca A, Ceccherini-Silberstein F, Gianotti N, Torti C, Bonora S, Zazzi M, Balotta C.

BMC Infect Dis. 2014 Jul 18;14:398. doi: 10.1186/1471-2334-14-398.


Phylogenetic analysis provides evidence of interactions between Italian heterosexual and South American homosexual males as the main source of national HIV-1 subtype C epidemics.

Lai A, Bozzi G, Franzetti M, Binda F, Simonetti FR, Micheli V, Meraviglia P, Corsi P, Bagnarelli P, De Luca A, Ciccozzi M, Zehender G, Zazzi M, Balotta C.

J Med Virol. 2014 May;86(5):729-36. doi: 10.1002/jmv.23891.


Decreasing cardiovascular risk in HIV infection between 2005 and 2011.

De Socio GV, Parruti G, Ricci E, Maggi P, Celesia BM, Penco G, Martinelli C, Franzetti M, Di Biagio A, Bonfanti P, Pucci G, Schillaci G; CISAI study group..

AIDS. 2014 Feb 20;28(4):609-12. doi: 10.1097/QAD.0000000000000181.


Four years data of raltegravir-based salvage therapy in HIV-1-infected, treatment-experienced patients: the SALIR-E Study.

Capetti A, Meraviglia P, Landonio S, Sterrantino G, Di Biagio A, Lo Caputo S, Ammassari A, Menzaghi B, De Socio GV, Franzetti M, Soria A, Meschiari M, Sasset L, Pellicanò G, Mazzotta E, Trezzi M, Celesia BM, Melzi S, Carenzi L, Ricci E, Rizzardini G.

Int J Antimicrob Agents. 2014 Feb;43(2):189-94. doi: 10.1016/j.ijantimicag.2013.10.013.


Local and global spatio-temporal dynamics of HIV-1 subtype F1.

Lai A, Ciccozzi M, Franzetti M, Simonetti FR, Bozzi G, Binda F, Rosi A, Bonora S, De Luca A, Balotta C, Zehender G.

J Med Virol. 2014 Feb;86(2):186-92. doi: 10.1002/jmv.23783.


Systemic lupus erythematosus and HIV infection: a whimsical relationship. Reports of two cases and review of the literature.

Carugati M, Franzetti M, Torre A, Giorgi R, Genderini A, Strambio de Castilla F, Gervasoni C, Riva A.

Clin Rheumatol. 2013 Sep;32(9):1399-405. doi: 10.1007/s10067-013-2271-x. Review.


Safety and durability in a cohort of HIV-1 positive patients treated with once and twice daily darunavir-based therapy (SCOLTA Project).

Menzaghi B, Ricci E, Carenzi L, Parruti G, Orofino G, Guastavigna M, Madeddu G, Maggi P, Di Biagio A, Corsi P, Penco G, De Socio G, Martinelli C, Vichi F, Celesia BM, Franzetti M, Grosso C, Molteni C, Bonfanti P, Quirino T.

Biomed Pharmacother. 2013 May;67(4):293-8. doi: 10.1016/j.biopha.2012.12.005.


The use of nucleoside reverse transcriptase inhibitors sparing regimens in treatment-experienced HIV-1 infected patients.

Di Biagio A, Ricci E, Viscoli C, Mesini A, Menzaghi B, Carenzi L, Orofino G, Parruti G, Martinelli C, Madeddu G, De Socio GV, Franzetti M, Quirino T, Bonfanti P; CISAI Group..

Curr HIV Res. 2013 Apr;11(3):179-86.


Trends and predictors of non-AIDS-defining cancers in men and women with HIV infection: a single-institution retrospective study before and after the introduction of HAART.

Franzetti M, Adorni F, Parravicini C, Vergani B, Antinori S, Milazzo L, Galli M, Ridolfo AL.

J Acquir Immune Defic Syndr. 2013 Apr 1;62(4):414-20. doi: 10.1097/QAI.0b013e318282a189.


HIV-1 subtype F1 epidemiological networks among Italian heterosexual males are associated with introduction events from South America.

Lai A, Simonetti FR, Zehender G, De Luca A, Micheli V, Meraviglia P, Corsi P, Bagnarelli P, Almi P, Zoncada A, Paolucci S, Gonnelli A, Colao G, Tacconi D, Franzetti M, Ciccozzi M, Zazzi M, Balotta C.

PLoS One. 2012;7(8):e42223. doi: 10.1371/journal.pone.0042223.


96 Week follow-up of HIV-infected patients in rescue with raltegravir plus optimized backbone regimens: a multicentre Italian experience.

Capetti A, Landonio S, Meraviglia P, Di Biagio A, Lo Caputo S, Sterrantino G, Ammassari A, Menzaghi B, Franzetti M, De Socio GV, Pellicanò G, Mazzotta E, Soria A, Meschiari M, Trezzi M, Sasset L, Celesia BM, Zucchi P, Melzi S, Ricci E, Rizzardini G.

PLoS One. 2012;7(7):e39222. doi: 10.1371/journal.pone.0039222.


High burden of transmitted HIV-1 drug resistance in Italian patients carrying F1 subtype.

Franzetti M, Lai A, Simonetti FR, Bozzi G, De Luca A, Micheli V, Meraviglia P, Corsi P, Bagnarelli P, Almi P, Zoncada A, Balotta C.

J Antimicrob Chemother. 2012 May;67(5):1250-3. doi: 10.1093/jac/dks013.


Transmission of resistant HIV type 1 variants and epidemiological chains in Italian newly diagnosed individuals.

Lai A, Violin M, Ebranati E, Franzetti M, Micheli V, Gismondo MR, Capetti A, Meraviglia P, Simonetti FR, Bozzi G, Ciccozzi M, Galli M, Zehender G, Balotta C.

AIDS Res Hum Retroviruses. 2012 Aug;28(8):857-65. doi: 10.1089/AID.2011.0245.


Transmitted HIV Type 1 drug resistance and Non-B subtypes prevalence among seroconverters and newly diagnosed patients from 1992 to 2005 in Italy.

Riva C, Lai A, Caramma I, Corvasce S, Violin M, Dehò L, Prati F, Rossi C, Colombo MC, Capetti A, Franzetti M, Rossini V, Tambussi G, Ciccozzi M, Suligoi B, Mussini C, Rezza G, Balotta C.

AIDS Res Hum Retroviruses. 2010 Jan;26(1):41-9. doi: 10.1089/aid.2009.0057.


Supplemental Content

Loading ...
Support Center